அலெக்சாண்டர் பாஷ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
EQS-News: Signature of a Memorandum of Understanding with Perfect Holding SA
boersennews.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boersennews.de Daily Mail and Mail on Sunday newspapers.
EQS-News: Kinarus AG: Signature of a Memorandum of Understanding with Perfect Holding SA
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Kinarus further strengthens its leadership with two reputed industry experts
EQS Group-News: Kinarus AG / Key word(s): Personnel/Private Equity
26.04.2021 / 07:01
Hari Kumar, former CEO of Adheron Therapeutics, Inc. appointed Chairman of the Board of Directors
Thierry Fumeaux, MD, former member of Swiss National Covid Taskforce, joined Kinarus as new Chief Medical Officer
Basel, Switzerland, April 26, 2021. Kinarus AG, a Swiss clinical-stage biopharmaceutical company and owner of KIN001, a differentiated therapeutic candidate for the treatment of multiple diseases with high unmet need, announced today the appointment of Hari Kumar as Chairman of the Board of Directors and Thierry Fumeaux as Chief Medical Officer.
EQS-News: Kinarus further strengthens its leadership with two reputed industry experts
Kinarus AG,
Dr. Hari Kumar s long career took him from Roche to Eisai Ltd where he served as European Marketing Director. He returned to Roche as Global Head of Transplant Immunosuppressives. He subsequently moved to Amira Pharmaceuticals Inc. in 2007 as Chief Business Officer before becoming Chief Executive Officer of Adheron Therapeutics Inc.? In his career, Dr. Kumar oversaw the launch of the immunosuppressive, CellCept(R), the Alzheimer s drug, Aricept(R) and the gastric ulcer drug, Aciphex(R). At Amira, Dr. Kumar led the process that resulted in its acquisition by Bristol Myers Squibb in 2011. He also navigated the acquisition of Adheron Therapeutics by Roche, in his role as CEO/ Board member. These transactions have delivered over a billion dollars in returns to investors.
vimarsana © 2020. All Rights Reserved.